Placebo-corrected change in daytime office blood pressure over 8 h after consumption of lactotripeptide (LTP) milk on days 1 and 29 of intervention (data are presented as LsMean±s.e.m., *Po0.05).
This study shows that consumption of fermented lactotripeptides (LTPs)-containing milk may have an acute daytime effect on blood pressure that appeared sustained with daily intake over a period of 4 weeks. Angiotensin 1-converting enzyme (ACE) inhibition by LTPs could not be confirmed in plasma.
The fermented milk-derived lactotripeptides (LTPs) isoleucyl-prolyl-proline and valine-prolylproline, are identified to help lower blood pressure by ACE inhibition. Several placebo-controlled studies show that ingestion of LTP-containing fermented products for several weeks can reduce systolic and diastolic blood pressure (SBP/DBP) in high normal-to-mild hypertensive subjects. [1] [2] [3] [4] [5] [6] [7] [8] [9] However, limited information about the acute effects of LTPs during the first hours after ingestion is available. Thus, it remains unknown whether intake at frequencies less than daily over weeks would have similar blood pressure-lowering effects. It has been hypothesized that LTPs work through ACE inhibition and that pharmacological ACE inhibitors have immediate hypotensive effects after ingestion.
We therefore investigated the effect of LTPs on blood pressure during the first 8 h after intake, and compared these acute effects with daytime effects after 4 weeks of intervention. We also studied effects on plasma markers of the renin angiotensin system. Participants qualified for the study when they were between 35 and 70 years, had average SBP between 130 and 160 mm Hg and DBPo100 mm Hg. Exclusion criteria were the use of medication, nonnormal results of biochemical analysis of blood and urine, alcohol abuse, milk allergy and pregnancy.
In a double-blind, randomized crossover design, 42 participants consumed for 4 weeks each a fermented LTP-containing product and a placebo product, with a 4-week washout period in between. On active treatment, subjects consumed daily 250 ml skimmed milk with a Lactobacillus helveticus and Saccharomyces cerevisiae fermented milk powder added containing 15.9 mg l À1 isoleucylprolyl-proline and 18.7 mg l À1 valine-prolyl-proline. On placebo treatment, subjects consumed a similar drink with skimmed milk powder without LTP added.
Effects on days 1 and 29 of each treatment were measured for 8 h after ingestion of the study products by measuring office blood pressure with an oscillometric automatic device (Omron IC) at 45-min intervals. At day 15 (±7 days), blood samples were taken fasted and at 10 occasions post-intake of the study products (over 8 h) for determination of plasma levels of ACE-activity, angiotensin I, angiotensin II and active plasma renin concentration.
Based on a within-subject variance in SBP of 42 observed in previous experiments, this study had an a priori power of 80% at a ¼ 0.05 to detect a decrease in SBP of 5 mm Hg. The effects of treatments were evaluated by means of an analysis of variance including treatment, intervention period, treatment order and subject in the model (SAS Software 9.1). For office measurements, the 8 h of each day (1 or 29) were averaged, and then changes from baseline (time 0 of day 1 of each intervention period) were calculated and used as response variables for the analysis.
Forty-two subjects were randomized, and 40 subjects were included in statistical analysis. There were no significant differences in baseline characteristics between the two treatment order groups. Although all subjects fulfilled the inclusion criteria at screening (mean SBP/DBP 148.5( ± 5.9)/ 89.3(±6.9) mm Hg), the average starting blood pressure level was lower than that set in the inclusion criteria (129.6 ( ± 1.5)/80.7 ( ± 1.3) mm Hg at the start of active treatment and 127.9 (±1.5)/80.9 ( ± 1.3) mm Hg at the start of placebo). The baseline SBP and DBP values measured in office were also lower in the second (124.7 (±1.5)/78.6 (±1.3) mm Hg) than in the first treatment period (132.8 ( ± 1.5)/83.1 ( ± 1.3) mm Hg; Po0.001).
In all subjects together, LTP milk tended to decrease SBP (Figure 1 ; P ¼ 0.057) relative to placebo. DBP was not significantly affected (P ¼ 0.549). At day 29, the acute effects on SBP and DBP were similar but not significant (P ¼ 0.191 and P ¼ 0.391, respectively).
In a post hoc subgroup analysis, treatment with LTP milk showed larger decreases in both SBP (P ¼ 0.01 and P ¼ 0.07 for days 1 and 29, respectively), and DBP (P ¼ 0.18 for both days) in participants that met the initial blood pressure criteria at the start of the study (SBP4130 mm Hg; Figure 1 ).
Lactotripeptide milk did not significantly affect plasma levels of angiontensin I, angiotensin II, ACE activity and active plasma renin concentration, but it significantly decreased the angiotensin II/angiotensin I ratio by 29% (P ¼ 0.035; see Supplementary Information).
The present study results indicate that consumption of fermented LTP-containing milk may decrease SBP during 8 h immediately after ingestion. This daytime effect on blood pressure appeared sustained after 4 weeks of intervention, without the observation of any additional chronic effect. Post hoc analysis suggests that this LTP-induced effect on blood pressure was more pronounced in subjects with higher baseline SBP. The current data support the hypothesis that consumption of LTP milk does not need sustained consumption for a beneficial effect on blood pressure. It might be possible that LTP acts through ACE inhibition, but this was not confirmed by the plasma ACE levels.
Aihara et al. 1 did not find an acute effect of LTP, but in that study blood pressure was measured only once at 2-3 h after intake. This might have been insufficient to detect an effect, because blood pressure is highly variable. We repeated blood pressure measurements every 45 min over a period of 8 h after intake of the test product. The acute effect of LTP on SBP observed here in humans is rather modest as compared to that in SHR rats. 10 Next to species difference, a possible explanation for this difference is that the individuals in the present study had normal-to-mildly elevated blood pressures, while SHR rats are essentially hypertensive. It has been proposed that a reduction in blood pressure is larger with higher starting blood pressure levels. 1, 7 This is supported by our observation that the reduction in SBP was larger in the subgroup of subjects with higher blood pressure at the start of the intervention.
Compared to the studies in literature, the product tested in this study might have contained sufficient isoleucyl-prolyl-proline and valine-prolyl-proline to induce additional blood pressure-lowering after 2-4 weeks of intervention. [1] [2] [3] Other studies suggest that 2-4 weeks is not long enough and that at least 6-12 weeks of intervention are needed to elicit a longerterm LTP-induced effect. [4] [5] [6] [7] [8] The latter studies are more in line with our observation, as we did not observe a significant additional 4-week effect. Therefore, we can only speculate that the blood pressure-lowering effect is already present at the first day of consumption and that this effect is repeated on every new day that the LTP-containing product is consumed, with only a very small additional chronic effect after at least 6 weeks of intervention.
In conclusion, fermented LTP-containing milk lowers blood pressure already on the first day of consumption, but more evidence is needed to prove ACE inhibition as a mechanism of action.
